We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

21 hedge funds and large institutions have $2.1M invested in Titan Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

13% less funds holding

Funds holding: 24 → 21 (-3)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

41% less capital invested

Capital invested by funds: $3.55M → $2.1M (-$1.45M)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
4
Closed
6
Calls
$66K
Puts
–
Net Calls
+$66K
Net Calls Change
+$67K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$193K
2
WS
Wedbush Securities
California
+$24.9K
3
Northern Trust
Northern Trust
Illinois
+$12.4K
4
BlackRock
BlackRock
New York
+$6.22K

Top Sellers

Rank Fund Capital Flow
1
MERSOM
Municipal Employees' Retirement System of Michigan
Michigan
-$531K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$168K
3
Millennium Management
Millennium Management
New York
-$162K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$63K
5
GS
Gagnon Securities
New York
-$61K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$732K +$193K +31 +25%
Vanguard Group
2
Vanguard Group
Pennsylvania
$494K -$168K -27 -21%
WPA
3
Winning Points Advisors
Florida
$183K -$12.4K -2 -5%
Millennium Management
4
Millennium Management
New York
$169K -$162K -26 -43%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$115K – – –
BlackRock
6
BlackRock
New York
$87K +$6.22K +1 +6%
Northern Trust
7
Northern Trust
Illinois
$71K +$12.4K +2 +15%
Bank of America
8
Bank of America
North Carolina
$49K – – –
SRAM
9
Stone Ridge Asset Management
New York
$41K +$56K +9 New
California Public Employees Retirement System
10
California Public Employees Retirement System
California
$37K – – –
Bank of New York Mellon
11
Bank of New York Mellon
New York
$18K – – –
WS
12
Wedbush Securities
California
$18K +$24.9K +4 New
TSS
13
Two Sigma Securities
New York
$16K -$6.22K -1 -25%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$16K – – –
WAM
15
Wealthspire Advisors (Maryland)
Maryland
$16K – – –
CCB
16
Cutter & Co Brokerage
Missouri
$13K – – –
Morgan Stanley
17
Morgan Stanley
New York
$9K – – –
WIM
18
Westside Investment Management
California
$4.04K – – –
MAM
19
Meeder Asset Management
Ohio
$4K – – –
APA
20
American Portfolios Advisors
New York
$3.62K +$6.22K +1 New
BCM
21
Blume Capital Management
California
$3K – – –
AG
22
Advisor Group
Arizona
$2K – – –
CIBC Private Wealth Group
23
CIBC Private Wealth Group
Georgia
$1K – – –
DOA
24
D'Orazio & Associates
Virginia
$1K – – –
KF
25
Krilogy Financial
Missouri
$1K – – –
1
2

TTNP Hedge Fund Activity: Q4 2017 in Review

21 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2017, worth a combined $2.1M — down 41% from $3.55M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of TTNP and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $193K. The largest seller was Municipal Employees' Retirement System of Michigan, exiting entirely with an estimated $531K sold.

  • 21 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2017, down from 24 in Q3 2017.
  • Funds reported $2.1M of Titan Pharmaceuticals stock for Q4 2017, down 41% quarter-over-quarter.
  • 3 funds opened new Titan Pharmaceuticals positions in Q4 2017 and 6 closed out, a net change of -3 holders.
  • The largest Titan Pharmaceuticals buyer in Q4 2017 was Renaissance Technologies, an estimated $193K added.
  • The largest Titan Pharmaceuticals seller in Q4 2017 was Municipal Employees' Retirement System of Michigan, an estimated $531K sold.

Based on aggregated 13F filings for Q4 2017.